This Stock Offers Juicy Option Premiums, But Also Is Highly Risky

Implied volatility currently sits at 87%, close to the highest levels for Tempus AI stock in the last 12 months.

Investors Business Daily • 3 hours ago

The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.

24/7 Wall Street • Oct 27, 2026

Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification covers Tempus' quality management system for "next-generation sequencing devices for cancer genomic profiling to support clinical management." xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A.

Business Wire • Oct 26, 2026

Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction with Big Pharma partnerships. TEM's differentiated model leverages AI-driven diagnostics and data licensing, generating immediate revenues rather than relying on speculative milestone payments. Strategic acquisition of Personalis positions TEM to capitalize on the rapidly expanding minimal residual disease (MRD) cancer testing market.

Seeking Alpha • Oct 23, 2026

Tempus AI: Less Risky Than When I Said Buy

Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow, with adjusted EBITDA turning positive. The Personalis acquisition secures MRD capabilities, integrating high-demand data and supporting pharma partnerships, while xT CDx FDA approval enables significant pricing uplift from 2027. The Data and Applications segment maintains robust ~28% growth, with a growing backlog and margins stabilizing despite headline deceleration and compute cost pressures.

Seeking Alpha • Oct 23, 2026

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus's largest li.

Business Wire • Oct 23, 2026

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions. BMS also leads Pathos's Series E financing and gains access to Pathos Foundry across its broader R&D portf.

Business Wire • Oct 23, 2026

How Tempus AI Built a Defensible Data Moat in Precision Healthcare

As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data, specialized models, and integration into diagnostic workflows.

ETF Trends • Oct 22, 2026

Here's How Tempus AI Demonstrates Improving Operating Leverage

TEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.

Zacks Investment Research • Oct 19, 2026